Q-omics provides the consensus-scored RFLNA profile across patient tissues and cancer cell-line models. RFLNA expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RFLNA is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, RFLNA RNA expression shows 15,004 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, LUAD, and TGCT as cancer lineages where RFLNA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RFLNA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RFLNA survival associations across molecular data types. RFLNA RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RFLNA RNA expression–survival associations across cancer types. High RFLNA expression shows unfavorable associations in MESO, UVM, HNSC and KIRP, but favorable associations in UCS and DLBC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RFLNA RNA expression.
This table summarizes RFLNA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RFLNA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RFLNA shows higher tumor expression in LUAD, THCA, LUSC, HNSC, BLCA and LIHC. The LUAD box plot shows higher RFLNA RNA expression in tumor versus normal tissue (log2 FC = +2.083, t-test p < 0.001).
This table shows molecular features associated with RFLNA in patient tissues and cancer cell lines. In patient samples, RFLNA shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RFLNA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
